Nucleus Network to acquire Hammersmith Medicines Research.

Nucleus Network, an early phase clinical research company, agreed to acquire Hammersmith Medicines Research, an early phase clinical trial organisation. Financial terms were not disclosed. “We are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR’s legacy. This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered,” Teena Pisarev, Nucleus Network CEO.